Lipid Luminations: Recent Episodes

ReachMD

Get to the heart of the most recent advances in lipid management and cardiovascular disease with Lipid Luminations, which features scientific and clinical research updates, novel emerging treatment options, and best practices in patient care.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Robert Kloner, Vice President of Translation at Huntington Medical Research Institutes and Professor of Medicine in the Cardiovascular Division of Keck School of Medicine at the University of Southern California.

Dr. Kloner discusses the cardiovascular risk factors associated with erectile dysfunction, safety and efficacy of erectile disfunction drugs, and benefits vs risks of supplementing with testosterone.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Rhoda Cooper-DeHoff. Dr. Cooper-DeHoff is an Associate Professor in the Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine of the Colleges of Pharmacy and Medicine at the University of Florida. She is also Associate Director of the Center for Pharmacogenomics at this institution.

Dr. Cooper-DeHoff discusses the rise of pharmacometabolomics, genomic testing, and pharmacogenetic testing in lipidology, with particular emphasis on predictive mapping for statin responses.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dave Dixon, PharmD, Clinical Pharmacist and Associate Professor of Pharmacology at Virginia Commonwealth University School of Pharmacy. Dr. Dixon is also a Board Certified Pharmacotherapy Specialist, Clinical Lipid Specialist, and Fellow of the National Lipid Association. He serves as a Regional Representative for the Southeast Chapter of NLA and on the Journal of Clinical Lipidology Editorial Board.

Dr. Dixon discusses guidelines for treating hypertriglyceridemia, effective therapies for reducing triglyceride levels, and emerging lipid-lowering therapies in development.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Eugenia Gianos. Dr. Gianos is an assistant professor in the Department of Medicine and co-clinical director of the Center for the Prevention of Cardiovascular Disease at the NYU School of Medicine.

Dr. Gianos discusses the effectiveness, potential side effects, and patient outcomes with PCSK9 antibodies for management of dyslipidemia.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Patients in lipidolgy clinics sometimes undergo diagnostic workups for mild liver enzyme elevations, and in select cases a diagnosis of non-alcoholic fatty liver disease will be made. How does this diagnosis compare with the more inflammatory alcoholic fatty liver disease, and what roles should the lipidologist play in response to these findings?

Dr. David Cohen, Professor of Medicine at Harvard Medical School and Director of Hepatology at Brigham and Women's Hospital, joins host Dr. Alan Brown to discuss the pathogenesis and management of non-alcoholic fatty liver disease.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Like in the United States, Canadian citizens contend with a high pediatric prevelance of lipid disorders, particularly familial hypercholesterolemia. However, perspectives on clinical care and standards public health priorities to address dyslipidemia differ markedly between these two countries. Can American practitioners and health policy experts alike benefit from Canadian approaches to lipidology?

Dr. Alan Brown welcomes Dr. Julie St. Pierre, Professor of Pediatrics at Sherbrooke University in Canada, to discuss pediatric lipid disorder management across North American borders.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Joining Dr. Alan Brown to discuss the pharmacokinetic data behind drug interactions between treatments for complex lipid abnormalities is Dr. Barbara Wiggins, Pharm.D, clinical pharmacy specialist in cardiology at the Medical University of South Carolina and adjunct professor at the South Carolina School of Pharmacy. Dr. Wiggens has served as a member of the cardiovascular expert panel for the United States Pharmacopoeia.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Robert Wild, MD, MPH, D.Phil.

Recorded live at the recent Annual National Lipid Association meeting, Dr. Alan Brown welcomes Dr. Robert Wild to discuss types of dyslipidemia that clinicans may see in women of child bearing age, particularly those using hormonal contraception. The two discuss ways for clinicians to trace the source of dyslipidemia in these women, from primary to secondary causes, and how this knowledge can guide future contraception choices.

Dr. Robert Wild is Professor of OB/GYN and Adjunct Professor in Biostatistics and Epidemiology at the University of Oklahoma. He is also Adjunct Professor in Epidemiology at the University of Pittsburgh, and Adjunct Professor of Nutrition at Oklahoma State University.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Joyce Ross

Host Dr. Alan Brown welcomes Joyce Ross, nurse practitioner and President of the National Lipid Association. Joyce is a consultative education specialist in Cardiovascular Risk Intervention with the University of Pennsylvania Health System. She is the first Nurse Practitioner elected as President of the NLA.

Ms. Ross introduces her goals for the upcoming year, including novel efforts on behalf of the NLA to help combat America's obesity epidemic.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown welcomes Dr. Seth Martin, cardiologist and assistant professor of medicine at the Johns Hopkins University School of Medicine with a joint appointment in epidemiology at the Johns Hopkins Bloomberg School of Public Health. Dr. Martin is a faculty member in the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease.

Dr. Martin discusses the pursuit of lipid profiles on a national level, utilizing Big Data from health records and clinical trials to develop better understandings of cardiovascular risk and theraputic efficacies.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA

Host Dr. Alan Brown welcomes Joyce Ross, MSN, CRNP, FNLA, President-Elect of the National Lipid Association. Joyce serves as a consultative education specialist in cardiovascular risk intervention with the University of Pennsylvania Health System. Their discussion focuses on lipid management to reduce atherosclerotic cardiovascular disease (ASCVD) risk in elderly patient populations. Thhis interview was recorded live at the National Lipid Association in San Diego, California for the 2016 Spring Clinical Lipid Update.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Dr. Alan Brown welcomes Dr. Penny Kris-Etherton, Distinguished Professor of Nutrition at Penn State and Past President of NLA. Dr. Kris-Etherton reviews the current dietary recommendations for saturated fat for the population at large and for reducing LDL-C levels. The two discuss the evidence to support these dietary recommendations and optimal replacement nutrients for dietary saturated fatty acids (SFAs).

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown welcomes Dr. Steven Nissen, Chairman of the Department of Cardiovascular Medicine and Professor of Medicine at the Lerner School of Medicine of the Cleveland Clinic. The two focus on some of the major developments in lipidology today, from roles of intravascular ultrasound to updates in clinical drug trials to perspectives on past and present guideline recommendations.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Harold Bays, MD, FNLA

Dr. Alan Brown welcomes Dr. Harold Bays, President of the Southeast Lipid Association and President of the Louisville Metabolic and Atherosclerotic Research Center in Louisville, KY. Dr. Bays led a novel educational effort to provide an annual summary of clinical lipidology to readers of the Journal of Clinical Lipidology. With insightful commentaries of value to lipidologists and generalists alike, the annual summary is expected to pave new ground in the ongoing effort to keep clinicians up to date with the field.

Host: Patrice L Basanta-Henry, MD, MHSc, FACOG

Host Dr. Patrice Basanta Henry welcomes Dr Nzinga Harrison, Addiction Medicine & Psychiatrist, Campaign Psychiatrist for Let's Get Mentally Fit!, and, the CMO of ANKA Behavioral Health Incorporated. Dr. Harrison will discuss the importance of non-pyschiatric clinicians in recoginizing mentail illness, those specific illnesses where there is a higher chance of comorbidity of psychiatric illness, and best practices & tools avaialble for health care providers.

Host: Harold Bays, MD, FNLA

Dr. Harold Bays welcomes Dr, Alan Remaley, clinical pathologist and Section Chief of the Lipoprotein Metabolism Section in the Cardiopulmonary Branch of the National Heart Lung, and Blood Institute in Bethesda, MD. Their discussion centers on LDL cholesterol from a variety of little-known aspects: its history as a biomarker for disease status, the ways in which it gets specifically measured, and the rise of lipid-altering pharmacotherapies to combat excessive LDL levels.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Allan Sniderman, MD

Risk is calculated by a variety of algorithms, all of which produce an estimate for that individual based on age, gender, cholesterol, blood pressure, and smoking history. The estimate is critical to clinical decision-making, but how accurate is it? Host Dr. Alan Brown welcomes Dr. Allan Sniderman, Edwards Professor of Cardiology at McGill University, to discuss why we should pay more attention to the causes, and less to the risks, of cardiovascular disease.

Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Medication Adherence: is it the Achilles Heel in your therapies for patients with dyslipidemia? Dr. Lynne Braun, nurse practitioner in the Preventive Cardiology Center and the Heart Center for Women, and Professor in the Department of Adult Health Nursing at the Rush College of Nursing in Chicago, targets three critical barriers to lipid medication adherance: weak patient-provider relationships, health illiteracy, and poor health care transitions after hospital discharge.

Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Dr. Alan Brown welcomes Dr. Peter Jones, Associate Professor of Medicine and Atherosclorosis/Lipidology at Baylor College of Medicine in Houston, TX. They review special populations in the treatment of dyslipidemia, including Asians, women, elderly patients, and the immune-compromised.

Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Keith C. Ferdinand, MD

Host Dr. Alan Brown is joined by Dr. Keith C. Ferdinand, Professor at Tulane University School of Medicine in New Orleans, Louisiana. Dr. Ferdinand reviews the etiologies, diagnostic challenges, and management considerations for selective cardiac health issues prevalent in African American populations, from hypertension to coronary arterial calcium plaques to lipid levels.

Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA

One of the most recurrent questions that cardiologists and lipidologists face in daily practice is how to best approach the elderly patient with dyslipidemia. Joining Dr. Alan Brown for special considerations in this population and guideline-based recommendations for management is Joyce Ross, certified registered nurse practitioner, clinical lipid specialist, and President-Elect of the National Lipid Association.

Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown welcomes Dr. Don Wilson, Endocrinologist at Cook Children's Health Care System, Fort Worth, Texas. Dr. Wilson will review dyslipidemia in children and adolescent patients. Key points of their discussion will cover the association between abnormal lipid levels in children and an increased lifetime risk of atherosclerotic CVD, as well as, the CVD risk factors present in children and how it tracks from childhood to adulthood.

Supported by an Educational Grant from AstraZeneca.

Supported by an Educational Grant from AstraZeneca. - See more at: https://reachmd.com/programs/lipid-luminations/million-hearts-initiative-dr-janet-wright-executive-director/7439/#sthash.aVHL9OOn.dpuf Supported by an Educational Grant from AstraZeneca. - See more at: https://reachmd.com/programs/lipid-luminations/million-hearts-initiative-dr-janet-wright-executive-director/7439/#sthash.aVHL9OOn.dpuf

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

In this session of Lipid Luminations, host Dr. Alan Brown welcomes Dr. Merle Myerson, founder and director of the Cardiovascular Disease Prevention Program, Lipid Clinic, Pre-Exercise Heart Screening Program, and Cardiology Section/Institute for Advanced Medicine (HIV) at Mount Sinai St. Luke's and Mount Sinai Roosevelt Hospitals. Dr. Myerson reviews the guidelines for prevention, diagnosis, and management of dyslipidemia in patients with HIV.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Janet Wright, MD

Heart disease and stroke are two of the leading causes of death in the United States. The Department of Health and Human Services, with several key partners, launched the Million Hearts national public-private initiative. Million Hearts aims to prevent one million heart attacks and strokes over five years through behavioral changes and clinical interventions. Host Dr. Alan Brown welcomes Dr. Janet Wright, Executive Director of Million Hearts in Washington, DC.

Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

An old clinical dogma in OB/GYN was that dyslipidemia during pregnancy wouldn't have any long term implications on the developing fetus because of short exposures at 9 months. This has since been shown to be untrue. What health issues surface in children whose mothers experienced abnormally elevated lipid levels in pregnancy, and how can these problems be prevented at the peripartum stage? Host Dr. Alan Brown joins Dr. Robert Wild, Professor of Obstetrics and Gynecology at the University of Oklahoma College of Medicine, to discuss prevention and treatment strategies for dyslipidemia during pregnancy. Dr. Wild is past president of the American Society of Preventive Cardiology, the Society of Reproductive Endocrinologists, the Oklahoma City Obstetrical and Gynecological Society, and the Menopause Group for the American Society of Reproductive Medicine.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

As many as 25% of patients taking statins may experience side effects. How should clinicians respond to the broad spectrum of side effects and variable severities reported? Host Dr. Alan Brown welcomes Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology at Duke University School of Medicine, to discuss statin intolerance and the most effective methods for counseling patients who experience this issue. Dr. Guyton's team has developed approaches that help many patients who have trouble taking statin drugs find alternative ways to lower their low-density lipoprotein (LDL) levels. Dr. Guyton is recognized nationally as an expert in clinical management of lipid disorders and is known for his earlier work on lipid deposition in the arterial wall.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

A paradigm shift in the management of lipid disorders has been witnessed of late based on evidence reviews by the AHA and the ACC. Where the clinical dogma once focused on targeting specific lipoproteins, clinicians are now trending toward using appropriate dosages of statins for lowering non-HDL cholesterol. What are the ramifications of this change in approach, and how does the NLA weigh in on recommendations for targets and goals? To address these and other questions, host Dr. Alan Brown welcomes Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

What's the evidence for LDL and other non-HDL targets for primary and secondary prevention of heart disease? What are the comparative benefits versus toxicities of all lipid-lowering medications in clinical use? Addressing these and other questions from the standpoing of recent NLA recommendations is Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL.

Produced in partnership with

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Carl Orringer, MD, FACC, FNLA

What are some of the causes of high triglycerides? What is the biggest health risk? And, for these patients, at what level is the risk greater for developing pancreatitis and coronary artery disease? Host Dr. Alan Brown welcomes Dr. Carl Orringer, Associate Professor of Medicine at the Cardiology Division, University of Miami Medical Center and Director of the Preventive Cardiovascular Medicine and LDL apheresis program. In this edition of Lipid Luminations, Dr. Orringer will discuss the management of the patients with triglycerides 200-499 mg/dl.

Guest: Kevin C. Maki, PhD, FNLA, CLS

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

At the most recent National Lipid Association (NLA) meeting, host Dr. Alan Brown welcomes Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty position in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL. Drs. Brown and Maki discuss the evidence of the relationship of statin use and risk of new onset of diabetes; as well as, the relationship of statin use and the possiblity of worsening glycemia in those patients who have diabetes. What are the conclusions? What should clinicians be screening for?

Download and listen to this great conversation!

Sponsored by

Guest: Anne Goldberg, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown is joined by Anne Goldberg, MD, Associate Professor of Medicine at Washington University School of Medicine and a member of the ACC/AHA Blood Cholesterol Guidelines Panel. Dr. Goldberg will provide a review of the panel assembled by National Heart, Lung, and Blood Institute to construct integrated guidelines for cardiovascular risk reduction. She will also address the controversy regarding the ACC/AHA recently published risk assessment and cholesterol guidelines.

Download and listen today!

Sponsored by

Guest: Kevin C. Maki, PhD, FNLA, CLS

Guest: Carl Orringer, MD, FACC, FNLA

Guest: Harold Bays, MD, FNLA

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Matthew Ito, PharmD, FNLA

Host Dr. Alan Brown is joined by an expert panel to discuss the NLA's latest draft document that will serve as recommendations to clinicians for the management of patients with dyslipidemia. The National Lipid Association's goal was to harmonize guidelines among what has been presented in the past by the ATP panel, the American College of Cardiology/American Heart Association Guidelines, and those also released in 2013 by the International Atherosclerosis Society. The NLA reaffirms the importance of understanding targets of treatment and goals for patients.

Our expert panelists:

Harold Bays, MD, FNLA - Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center; co-author of the National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia and co-author of the American Society of Bariatric Physicians Obesity Algorithm
Matthew Ito, PharmD, FNLA - Professor of Pharmacy Practice and Director of the Cardiovascular Pharmacodynamics Laboratory at Oregon State University/Oregon Health & Science University; member of the National Lipid Association Expert Panel on the Diagnosis and Treatment of Familial Hypercholesterolemia and the Recommendations for Patient-Centered Management of Dyslipidemia
Carl E. Orringer, MD, FACC, FNLA - Associate Professor of Medicine, Cardiology Division at the University of Miami Medical Center; Editorial reviewer …

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Is there a patient age at which statin therapy should be discontinued? Likewise, what does the current evidence tell us about initiating vs not initiating statin therapy in older patients? Joining Lipid Luminations to discuss these and other important questions is Dr. W. Virgil Brown, Charles Howard Candler Professor of Medicine Emeritus at Emory University School of Medicine in Atlanta, Georgia.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Joining host Dr. Alan Brown is Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology of the Division of Medicine-Endocrinology and Metabolism at Duke University School of Medicine. Their discussion will focus on data and results from HPS-2 THRIVE, a large-scale study comparing the use of statins and niacin versus statins alone. THRIVE stands for the Treatment of HDL to Reduce the Incidence of Vascular Events.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Health information technologies have evolved dramatically from simplistic documentation devices early on to sophisticated drivers of quality patient care today. This emergence is having a particularly positive effect on treatment for dyslipidemia. Joining host Dr. Alan Brown to reflect on a recent NLA manuscript of HIT's impact toward adherence to lipid therapy is Dr. Jerome Cohen, Emeritus Professor of Internal Medicine at Saint Louis University School of Medicine and Director of Preventative Cardiology Program at the Saint Louis University Health Sciences Center. Dr. Cohen has been active in cardiovascular research for more than two decades.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown welcomes Dr. Marc Hamilton, Professor at Pennington Biomedical Research Center in Baton Rouge, LA. Their convesation focuses on the cardiometabolic consequences of lengthy sitting times, such as in people with "desk job careers."

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Joining host Dr. Alan Brown is Michael B. Bottorff, Pharm.D., Professor and Chair in the Department of Pharmacy Practice at South College School of Pharmacy in Knoxville, Tennessee. Dr. Bottorff will be reviewing generic medications, from manufacturing processes to approval measures.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Speaking with host Dr. Alan Brown on the state of genetic testing for familial hypercholesterolemia (FH) is Dr. Joshua W. Knowles, MD, PhD, Instructor of Cardiovascular Medicine at Stanford University and Attending Physician of the Stanford Center for Inherited Cardiovascular Disease Familial Hypercholesterolemia (FH) Clinic.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Dr. Alan Brown is joined by Dr. Bart Duell, director of the Lipid Disorders Clinic at the Oregon Health and Sciences University and one of the top winners in the NLA Abstracts program, to discuss research updates in Familial Hypercholesterolemia (FH).

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Postprandial hypertriglyceridemia occurs when the rapid absorption of dietary fat (in the form of chylomicron triglycerides) overwhelms the body's ability to clear plasma triglyceride. In its most severe form, postprandial hypertriglyceridemia can lead to chylomicronemia and a greatly increased risk of acute, life-threatening pancreatitis. Joining host Dr. Alan Brown to talk about this condition and a trial drug treatment in research and development is Dr. Dan Meyers, one of the top winners in the Abstracts Program of the National Lipid Association's Annual Scientific Sessions. Dr. Meyers is currently a Translational Medicine Expert with Novartis Institutes of Biomedical Research (NIBR) in Cambridge, MA. While at NIBR, he has designed and executed first-in-human, proof of concept, and mechanistic studies with novel compounds intended for the treatment of dyslipidemia, diabetes and related metabolic disease.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Dr. Alan Brown is joined by Dr. Thomas Dayspring, Director of Cardiovascular Education for the Foundation for Health Improvement and Technology in Richmond, VA and clinical assistant professor of medicine at the UMDNJ - NJ Medical School. He is also a Fellow of both the American College of Physicians and the National Lipid Association. The two discuss Dr. Dayspring's research on discordances between LDL-P and ApoB, two biomarkers that are otherwise thought to correlate well with one another.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Dr. Alan Brown welcomes Dr. Daniel J. Rader, Cooper-McLure Professor of Medicine and Pharmacology and Chief of the Division of Translational Medicine and Human Genetics at the Perelman School of Medicine at the University of Pennsylvania. Their discussion focuses on the clinical diagnosis, genetic complexity and prevalence of HoFH while exploring the current and novel modalities available to help HoFH patients achieve their LDL goals.

Produced in Partnership with

Supported by an Educational Grant from

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Dr. Harold Bays, Chair for the National Lipid Association's expert panel on Adiposity, Obesity, and Dyslipidemia, discusses with host Dr. Alan Brown the panel's consensus statement published in the Journal of Clinical Lipidology.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Obesity is associated with systemic inflammation and oxidative stress, the leading steps towards development of atherosclerosis. Myloperoxidase (MPO) mediated oxidative damage of high-density lipoprotein (HDL) leads to a dysfunctional HDL which likely becomes pro-atherogenic. But, what happens in our adolescent patients? Monica Marin, MD, pediatric endocrinology fellow at the University of Oklahome Health Sciences Center and winner of the NLA Young Investigator Award, investigated the cardiovascular risk factors that are present in childhood and the importance of understanding the impact of oxidized HDL.

Download and listen today!

Produced in Partnership with

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Joining Dr. Alan Brown is Revathi Balakrishnan, MD, MPH, a general cardiology fellow at NYU and winner of the NLA Young Investigator Competition. Dr. Balakrishnan's research, titled "Prevalence of unrecognized prediabetes, diabetes and metabolic syndrome in patients undergoing non-urgent PCI," found that nearly 1 out of every 10 patients admitted to the NYU cardiac catheterization lab had diabetic hemoglobin A1c levels (6.5 and over) without a prior diagnosis of diabetes. An even larger proportion had prediabetes (57%) and metabolic syndrome (54%). Put another way, only 30% of the patients undergoing PCI had a normal glycemic status on admission. Drs. Balakrishnan and Brown reflect on these concerning results and discuss the need for a call to action among preventive cardiologists.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

There may be something unique about the avocado, far beyond its monosaturated fat content. Li Wang, graduate student at Penn State University and winner of the NLA Young Investigator Award, investigated this notion with a clinical study monitoring the effects of eating one avocado every day on risk factors for cardiovascular disease compared to a similar moderate fat diet without avocados, an average American diet, and a low-fat diet. Tune in for this discussion revealing her thought-provoking findings.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown is joined by David Tehrani, MS, a medical student at the University of California - Irvine School of Medicine and winner of the NLA's Young Investigator Competition for his research into the negative impact of inflammation on HDL's known cardioprotective effects. Tune in for new understandings on HDL and the inflammatory biomarkers attenuating its protective functions.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Rebecca S. Reeves, DrPH, RD, FADA

On this new edition of Lipid Lumoinations, host Dr. Alan Brown welcomes Dr. Rebecca Reeves, adjunct Assistant Professor of The University of Texas School of Public Health. Dr. Reeves will discuss the guidleines for children and adolescents as recommended by the Dietary Guidelines Advisory Committee. and review the nutrition guidelines for adults from the AHA, Dietary Guidelines for Americans 2010, and ATP III Therapeutic Lifestyle Change.

Tune in and listen!

Guest: Robert Wild, MD, MPH, D.Phil.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

What are the conditions associated with dyslipidemia pre-pregnancy that put women at greater risk for complications? What is the long term effect of having an obstetrical complication as CVD Risk for the mother and fetus? And, what is the major concern for hypertriglyceridemia in Pg and how do you treat it? Dr. Alan Brown, host, welcomes Dr. Robert A. Wild, who will address these questions and more during this discussion of Lipid Luminations. Dr. Wild is Professor of Reproductive Endocrinology, Obstetrics and Gynecology, Medicine, Family Medicine & Biostatistics and Epidemiology at the University of Oklahoma. And, he is Chief of the Gynecology Service at the VA Medical Center in Oklahoma City, OK.

Guest: Kevin C. Maki, PhD, FNLA, CLS

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan S. Brown is joined by Kevin C. Maki, PhD, FNLA, Chief Science Officer of Biofortis Clinical Research. Dr. Maki will review obesity, metabolic syndrome and type 2 diabetes mellitus as they are all insulin resistant states and are often characterized by atherogenic dyslipidemia or the "lipid triad" of elevated triglycerides, low HDL cholesterol and a predominance of small, dense LDL particles.

Guest: Janet Maxson, PhD, FNP

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan S. Brown welcomes Janet Maxson, NP, PhD, iPresident-Elect of the Midwest Lipid Association and the Director Women's Health at Minot Health & Wellness in Minot, North Dakota. Dr. Maxson is also a Fellow of the American Heart Association Council of Cardiovascular Nursing and the National Lipid Association. Dr. Maxson will review which calcium supplements are better for women, how much calcium is needed, and define the screening guidelines that are in place to screen women's bones in the context of heart disease.

Tune in for another great interview from Lipid Luminations!

Guest: Neil Stone, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Why is metabolic syndrome so important if it's not a disease? What have we learned from clinical trials about treating metabolic syndrome with lifestyle and/or drugs? And, what hurdles does the clinician face in trying to improve metabolic syndrome variables in the individual patient? Join Host Dr. Alan Brown as he welcomes Dr. Neil J Stone who will answer these questions and more. Dr. Stone is the Bonow Professor of Medicine at The Feinberg School of Medicine of Northwestern University and Distinguished Physician and Medical Director of the Vascular Center of the Bluhm Cardiovascular Institute of Northwestern Memorial Hospital in Chicago, Illinois.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Harold Bays, MD, FNLA

Host Dr. Alan Brown and guest, Dr. Harold Bays discuss the evolving treatments in lipid management and what we will be expecting in the future. They will address the role of niacin, the status of laropiprant, an overview of fish oils and omega-3 fatty acids and the novel approaches being used in today's research of lipid-altering drugs.

Harold E. Bays MD, FACP, FACE, FNLA is the Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center Inc. (L-MARC) in Louisville, KY. And, has served as an Investigator in over 400 Phase I - IV clinical trials for treatments for high cholesterol and other dyslipidemias, obesity, diabetes mellitus, hypertension, osteoporosis, and other metabolic and hormonal disorders. Dr. Bays has also served as Medical Director of L-MARC Research Center since 1989 - a clinical research facility originally established in 1989 - and President of L-MARC Research Center since its independent incorporation in 1998.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: William S. Harris, PhD

Host Dr. Alan Brown welcomes Dr. William "Bill" Harris on an important discussion facing our colleagues and ptients- "Are Fish Oils still cardioprotective?". Dr. Harris will address the recent randomized trials, how the trials differ from those done in the 1990s, and how clinicians should utlize the information in treating their patients.

Dr. William "Bill" Harris holds a PhD in Nutritional Biochemistry from the University of Minnesota. His research has focused on human lipid and lipoprotein metabolism, especially as they are affected by omega-3 fatty acids. He has been the principal investigator on 5 omega-3 related NIH grants, and since 2004 has been evaluating the RBC "omega-3 index" as a new risk factor for cardiovascular and neuropsychiatric diseases.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Debra Friedrich, DNP, ARNP, FNP-C, CLS

Join host Dr. Alan Brown and guest Dr. Debra Friedrich on the most common endocrine disorder in women- Polycystic Ovarian Syndrome (PCOS). They will review the epidemiology, prevalance, diagnosis, long-term risks and treatment options.

Dr. Debra Friedrich, DNP, ARNP, is an Assistant Professor at the University of South Florida College of Nursing and Director of the Family Nurse Practitioner Concentration. She is a family nurse practitioner and Clinical Lipid Specialist in practice in Bradenton, Florida.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Samuel Gidding, MD

Guidelines are being changed continuously as new evidence is acquired and our environment us evolve. Most recently released are the NHLBI guidelines for pediatric care providers. Host Dr. Alan Brown welcomes Dr. Samuel Gidding. They will address the context to which the guidelines were developed, some of the key social and ethical issues faced by the panel, and a review of the results and the recommendations for the future. Dr. Samuel Gidding is the head of pediatric cardiology and interim director of heart failure and transplant at Nemours Cardiac Center, A. I. DuPont Hospital for Children, Wilmington, Delaware.

Guest: Dean A. Bramlet, MD, FACC, FACP

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Recently, the FDA released data that claimed some the adverse events of statin therapy may lead to diabetes. But, how great are those adverse events? Should physicians and their patients have great concern? Listen in as Dr. Alan Brown welcomes Dean Bramlett, MD as they discuss statin safety, statin toxicity and the overall effectiveness of statins. Dr. Bramlett is the medical director of the Heart and Lipid Institute of Florida in St. Petersburg, Florida; and, assistant consultant professor at Duke University.

Brought to you by:

Guest: Peter Toth, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown is joined by Peter P. Toth, MD, PhD, director of preventive cardiology in Sterling Rock Falls Clinic and clinical professor at the University of Illinois School of Medicine in Peoria, Illinois. Dr. Toth is the current president of the National Lipid Association.

One of the most intensively studied drugs are statins. However, will statins continue to be the miracle drugs that health care professionals and patients rely on? What are statins current role in therapy for dyslipidemia patients? In this discussion, Dr. Toth will address these questions. He will also review the new therapies for lowering LDL and whether LDL should continue to be the target for risk assessment and treatment.

Brought to you by:

Guest: Benjamin J. Ansell, MD, FACC, FACP, FNLA

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown welcomes Benjamin Ansell, MD, professor of medicine and cardiology at University of Califronia at Los Angeles, CA and co-director of the Cholesterol and Hypertension Management Program at UCLA. Dr. Ansell reviews the latest trials: dal-OUTCOMES and AIM-HIGH. Dr. Ansell will address the objectives and study designs of both studies and explain why the studies were stopped early. Drs. Brown and Ansell also discuss the future of HDL therapy.

Brought to you by:

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Jerome D. Cohen, MD

Statins play a critical role in reducing the risk of heart disease. Not only are the benefits greatly appreciated by both physicians and patients, the majority of statins are also well tolerated. Despite this, many patients discontinue statin therapy against medical advice, oftentimes without notifying their doctors. For this reason, the National Lipid Association embarked on a study that used internet surveys to determine why patients discontinue their statins. This was called the USAGE Study, and its results are the subject of this discussion. Host, Dr. Alan Brown welcomes Dr. Jerome Cohen, emeritus professor of Internal Medicine at St. Louis University School of Medicine.

For more information on the USAGE survey, including resources for patients and healthcare providers, please visit the USAGE website at www.StatinUSAGE.com.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Spencer Kroll, MD, PhD

The Food and Drug Administration has warned that patients taking cholesterol-fighting statins face a small increase in the risk of higher blood-sugar levels and of being diagnosed with diabetes. There has been conflicting information from several large trials about the effects of statin therapy on the development of diabetes and glycemic control.

Join host Dr. Alan Brown and Dr. Spencer Kroll, diplomate of the American Board of Clinical Lipidology and a board certified Internist. He also serves on the board of directors of the Northeast Lipid Association and runs The Cholesterol Treatment Center, a lipid clinic in Marlboro, New Jersey.

Guest: Janet Maxson, PhD, FNP

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Dr. Janet Maxon and host Alan Brown discuss the latest thinking on hormone replacement therapy, heart disease and the menopausal woman. They discuss the results of recent clinical trials, as well as when to initiate therapy, and side effects.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Mary Felando, MS, RD

Given that approximately one third of Americans currently have some degree of metabolic syndrome, host Dr. Alan Brown discusses the very pertinent topics of food intake, prevention, lowering lipids, and related diet issues with dietician Mary Felando. They discuss what an appropriate diet is, how physicians should react when there are changes in nutritional guidelines, and the relative importance of saturated and other dietary fats.

Guest: Michael H. Davidson, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Is there a difference between biomarker cardiovascular risk assessment for broad population studies vs the role in personalized medicine? And, in individual patients, if a difference is found between the Framingham score and the biomarker risk assessment, which is more likely to correctly predict risk? Host Dr. Alan Brown talks with Dr. Michael Davidson, director of preventive cardiology and associate vice chairman for continuing medical education at the University of Chicago, about the role of biomarkers in improving cardiovascular risk prediction and guiding treatment, compared to traditional risk factor assessment.

Guest: Paul Hopkins, MD, MSPH

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown continues his series of conversations demystifying familial hypercholesterolemia (FH), this week with Dr. Paul Hopkins, co-director of cardiovascular genetics and director of the Cardiovascular Disease Prevention Clinic at the University of Utah. They define FH from a genetics perspective, and discuss genetic causes, prevalence, populations with higher prevalence, and screening guidelines.

Guest: Harold Bays, MD, FNLA

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown discusses fat, exercise and cholesterol with Dr. Harold Bays, medical director and president of Louisville Metabolic and Atherosclerosis Research Center, an independent research center. They look at the properties of adipose tissue — what Dr. Bays calls adiposopathy, or "sick fat." Dr. Bays says that fat cells are very active in terms of helping determine the metabolic rate and subject to dysfunction. They discuss how the location of fat cells and gender of the patient may cause differential problems and may contribute to arteriosclerosis, the effect of exercise on fat and cholesterol, and what kind of exercise is best for overweight patients.

Guest: George L. Bakris, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown talks with Dr. George Bakris, director of the Hypertensive Disease Unit at the University of Chicago Pritzker School of Medicine, about lipid management in the hypertensive patient and its particular relevance to patients with chronic kidney disease. How do cardiovascular events differ in chronic kidney disease patients compared to the general population? And do statins work in dialysis patients? They discuss these questions and the conclusions of the Study of Heart and Renal Protection (SHARP).

Guest: Seth Baum, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

This program reviews the guidelines for determining which patients should receive coronary CT angiography (CCTA), highlights the differences between CCTA and coronary calcium testing, and explores the overall radiation risk of serial CCTA. Dr. Alan Brown talks to guest Dr. Seth Baum, expert on electrophysiology, interventional cardiology, coronary CT angiography, and clinical lipidology, and a founding member of the Society for Cardiovascular CT.

Guest: Christie Ballantyne, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Dr. Christie Ballantyne discusses with host Dr. Alan Brown the use of genetic testing in various phases of disease onset in patients facing heart disease. They talk about how clinicians can utilize the current technologies, what the costs are and the benefits. How does learning more about the genetic mutation behind familial hypercholesterolemia affect treatment? Dr. Ballantyne and Dr. Brown also discuss what new genetic testing techniques are on the horizon.

Brought to you by:

Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown discusses management issues and practical advice with certified registered nurse practitioner and clinical lipid specialist Joyce Ross, who says that familial hypercholesterolemia (FH) is the most common genetic disorder, and many who have it are totally unaware of their condition until a cardiovascular event occurs. Find out why early identification, in addition to fostering good lifestyle choices, can mean patients with FH can enjoy a normal lifespan when the disorder is treated throughout the lifespan.

Brought To You By:

Guest: Jennifer Robinson, MD, MPH

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Who should be tested for genetically elevated cholesterol, or familial hypercholesterolemia? And how do we decide when and how to treat? Host Dr. Alan Brown talks with Dr. Jennifer G. Robinson, director of the Lipid Research Clinic and co-director of the Prevention Intervention Center at the University of Iowa. They discuss who is at risk in families, what age to start testing children, as well as treatment guidelines for children, adolescents, adult men, and women before and after childbearing age. For example, how do we treat children who test positive for familial hypercholesterolemia as young as two years of age?

Guest: Robert Wild, MD, MPH, D.Phil.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

What are the components of useful, evidence-based data? Dr. Robert Wild discusses with host Dr. Alan Brown the spectrum of data — from expert opinion, to observational studies, to different types of analytic studies, including cross-sectional, case-controlled studies, cohort studies, and clinical trials — and the shortcomings and biases of each. Dr. Wild explores cardiovascular epidemiology, clinical interpretation of biostatistical principles and how to critically evaluate research, in order to better integrate evidence, experience and patient values in clinical decisions.

Guest: Edward Gill, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

The Society of Atherosclerosis Imaging and Prevention recently developed appropriate use criteria for carotid IMT. What is the procedure? Why is it used? Why is it controversial? Which patients are candidates? Dr. Edward Gill, professor of medicine in the division of cardiology in the department of medicine at the University of Washington and clinical professor of diagnostic ultrasound at Seattle University, talks with host Dr. Alan Brown about the details of the procedure and how to locate a center for the test.

Brought to you by:

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Penny Kris-Etherton, PhD, RD

Patients are bombarded with dietary advice for cardiovascular health. Dr. Penny Kris-Etherton, distinguished professor of nutrition in the department of nutritional sciences at Pennsylvania State University and president of the National Lipid Association, discusses with host Dr. Alan Brown how to evaluate and prescribe a variety of dietary approaches, including lipid-lowering diets, for a variety of outcomes. They look at risk factors to be evaluated in each patient, along with patient preferences and how the diet is to be implemented.

Brought to you by:

Guest: James Falko, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

About 1 in 500 people have familial hypercholesterolemia (FH), the genetic disorder characterised by very high levels of low-density lipoprotein in the blood. Host Dr. Alan Brown talks to Dr. James Falko, professor of medicine in the division of endocrinology, metabolism and diabetes at the University of Colorado, Denver, about technology behind LDL apheresis to remove LDL cholesterol from blood. They cover the frequency of the procedure, possible complications, and what the data shows about the benefits of LDL apheresis in FH patients with refractory hypercholesterolemia. Dr. Falko also directs physicians to resources for locating LDL apheresis sites in the United States and Canada.

Brought to you by:

Guest: Allen Taylor, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Dr. Allen J. Taylor, director of advanced cardiac imaging at the Washington Hospital Center in Washington, DC, joins host Dr. Alan Brown to discuss the practical application and appropriateness of imaging guidlines related to screening for cardiovascular risk as well as carotid intima-media thickness.

Brought to you by:

Guest: Kevin C. Maki, PhD, FNLA, CLS

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Dr. Kevin Maki, chief science officer of BioFortis-Provident Clinical Research, discusses the fundamentals of fatty acids with host Dr. Alan Brown.

Brought to you by:

The National Lipid Association

Guest: Anne Goldberg, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

The National Lipid Association Foundation is emphasizing awareness of the most common inherited form of high cholesterol, familial hypercholesterolemia. Endocrinologist Dr. Anne Goldberg, talks with host Dr. Alan Brown about how to recognize and treat this hereditary cause of early onset atherosclerosis. Research has shown that statin treatment should begin when patients are very young. How early in life can we start screening and treating children, and are there differences to consider when treating young male versus female patients?

Brought to you by:

Guest: Carl Orringer, MD, FACC, FNLA

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

The Medicare donut hole, underemployment, and loss of employment can all put patients in situations that make affording lipid medications difficult to impossibl. Host Dr. Alan Brown talks to Dr. Carl Orringer, director of the Lipid Clinic and Preventive Cardiovascular Medicine Program at University Hospitals Case Medical Center, about strategies for working with patients who are having trouble affording their lipid medications. The solutions include pill-splitting when appropriate, discount drug stores, and novel recycled drug repository programs which are available in 38 states. What can we do to help patients whose financial circumstances do not only make medication adherence challenges, but are also related to an unhealthy diet and limited access to opportunities for physical activity.

Brought to you by:

Guest: Michael H. Davidson, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

From reversing atherosclerosis with HDL modification to promising antibodies on the horizon for lowering LDL cholesterol, the science of lipidology is a quickly-evolving field. What is the role of the National Lipid Association in clinical practice for clinicians who may not be lipid specialists? Host Dr. Alan Brown talks to Dr. Michael Davidson, president of the National Lipid Association and director of Preventive Cardiology at the University of Chicago, about the most current topics in lipidology and how the NLA seeks to support clinicians.

Brought to you by:

Guest: Michael H. Davidson, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Lipid Luminations host Dr. Alan Brown and his guest, Dr. Michael Davidson, discuss the predictive value of lipid biomarkers and inflammatory markers, particularly when compared with traditional risk factors, as well as the process of developing consensus on the use of novel risk factors.

Brought to you by:

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: William S. Harris, PhD

What are the differences among fish-based omega-3s, plant-based omega-3s, and supplements? Find out what the recommendations are for individuals without known cardiovascular disease, as host Dr. Alan Brown talks with Dr. William Harris, director of the Cardiovascular Health Research Center at the Sanford School of Medicine, University of South Dakota in Sioux Falls.

Brought to you by:

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Keith C. Ferdinand, MD

Though metabolic syndrome has not been found to be higher in the African American population compared to other populations, African Americans' rates of illnesses related to metabolic syndrome are higher. What explains this riddle? Host Dr. Alan Brown talks with Dr. Keith Ferdinand, clinical professor in the cardiology division at Emory University, and chief science officer of the Association of Black Cardiologists, Inc.

Brought to you by:

Guest: Samuel Gidding, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

What age does atherosclerosis and increased risk of heart attacks begin? Can children be at risk, and under what conditions should children's cholesterol levels be checked? Host Dr. Alan Brown discusses lipids in pediatric patients with Dr. Sam Gidding, of the Nemours Cardiac Center at the Alfred I. duPont Hospital for Children in Wilmington, Delaware, and professor of pediatrics at the Jefferson Medical College.

Brought to you by:

Guest: Ralph LaForge

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Joining host Dr. Alan Brown, Ralph LaForge, clinical exercise physiologist at Duke University in the department of endocrinology, and senior faculty consultant to the diabetes division of the US Indian Health Service, discusses the health issues of the Native American population, and some of the novel treatment protocols being developed.

Brought to you by:

Guest: Luther Clark, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

What happens when 25 highly-accomplished experts get together to develop the guidelines that will influence clinical lipidology practice? Who makes up the expert panels that develop guidelines, how are critical issues identified, what kinds of evidence are considered, and what are the keys to a successful expert panel? Host Dr. Alan Brown sits down at the 2010 National Lipid Association Meeting with Dr. Luther Clark, professor of clinical medicine at the SUNY Downstate Medical Center in Brooklyn, New York, and global director for scientific affairs in athrosclerosis at Merck & Co. Dr. Clark speaks from his involvement in the development of guidelines for ATP I, ATP II and ATP III.

Brought to you by:

Guest: John Robin Crouse, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Host Dr. Alan Brown broadcasts from the 2010 National Lipid Association meeting in Chicago. His guest is Dr. John R. Crouse, professor of medicine and public health sciences at Wake Forest University in Winston-Salem, North Carolina. They focus on the results from the ACCORD lipid study.

Brought to you by:

Guest: Ann Liebeskind, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Dr. Ann Liebeskind, the clinical program director of Heart and Vascular Services at Affinity Health System's St. Elizabeth Hospital in Appleton, Wisconsin, joins host Dr. Alan Brown at the National Lipid Association's 2010 meeting in Chicago, to talk about her research on lipid management and the systematic approach she's developed to help more patients achieve their lipid goals.

Brought to you by:

Guest: Thomas Allison, PhD, MPH

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Cardiologists are proud of the general reduction of cardiovascular disease and death over the past 20 years, but there is still significant concern about the epidemic of obesity and diabetes on the future of cardiovascular disease. Dr. Tom Allison, consultant in cardiovascular disease and internal medicine at the Mayo Clinic, joins host Dr. Alan Brown to discuss trends in cardiovascular disease, what has changed the behavior of our patients and what are the biggest challenges to come.

Brought to you by:

Guest: John Foreyt, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

This week's guest says that Americans eat an average of 200 calories more than they need every day. A variety of behavioral and emotional issues account for the reasons why. How can we help our patients change their habits? And what new habits will help them the most? The answer may lie in small changes. Host Dr. Alan Brown talks with Dr. John Foreyt, director of the DeBakey Heart Center's Behavioral Medicine Research Center at the Baylor College of Medicine. Dr. Foreyt predicts that if we can't reverse the obesity trend, 98 percent of Americans will be obese by the year 2100.

Brought to you by:

Guest: Carol Garber, PhD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: James Whitehead

Dr. Carol Garber, associate professor of movement sciences at Columbia University, and Jim Whitehead, executive vice president of the American College of Sports Medicine, join host Dr. Alan Brown to discuss the ways that exercise benefits lipids, cardiovascular disease, diabetes, and other health problems. Find out how hard and how much patients need to exercise to get benefits, and more about the science of exercise as medicine.

Brought to you by:

Guest: W. Virgil Brown, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

HDL cholesterol is a risk factor for cardiovascular events. But does raising HDL cholesterol reduce the risk of cardiovascular events? Host Dr. Alan Brown's guest, Dr. Virgil Brown, professor emeritus at the Emory University School of Medicine, discusses HDL as a target of therapy, as a risk factor, and sub-fractions of HCL.

Brought to you by:

Guest: Tara Dall, MD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

What is the role of advanced lipid testing, and particle number testing in particular? How might this information change the way you treat your patients? Host Dr. Alan Brown talks with Dr. Tara Dall, medical director of Advanced Lipidology Early Detection Center for Heart Disease and Diabetes in Delafield, Wisconsin

Brought to you by:

Guest: Penny Kris-Etherton, PhD, RD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Simple dietary modifications can have cholesterol-lowering effects similar to the effect of starting doses of statin drugs. Dr. Penny Kris-Etherton, distinguished professor of nutrition at Penn State University, and host Dr. Alan Brown discuss dietary changes that can lower LDL cholesterol as well as lifestyle changes. Tune in to find out what we can we do as clinicians to help our patients make lifestyle changes that may stave off disease.

Brought to you by:

Guest: Lawrence Rudel, PhD

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Our patients are exposed to a lot of information about the dangers of trans fatty acids, and new information about monounsaturated fats. Many of us may find that patients are confused by reports they read in the popular media. What can we tell them that will make a positive difference in how they read food labels? Joining host Dr. Alan Brown is Dr. Lawrence Rudel, professor of pathology and biochemistry and head of the lipid sciences section of the pathology department at the Wake Forest University School of Medicine.

Brought to you by:

Guest: Wahida Karmally, PH, RD, CDE, CLS

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

You can't follow your patients to the supermarket or sit down with them at the dinner table. What advice can you give them about healthy dietary oils and fats and the relative risks of unhealthy fats in the short time you have to educate patients in your office? Host Dr. Alan Brown asks these questions and more of Dr. Wahida Karmally, director of nutrition at the Irving Center for Clinical Research at Columbia University Medical Center in New York.

Brought to you by:

Guest: Julia Steinberger, MD, MS

Host: Larry Kaskel, MD

A series of well-established risk factors define the metabolic syndrome in adults. The situation is less clear for our younger patients, as they typically do not develop cardiovascular disease or experience cardiac events. The key for kids, it seems, is to determine their risk for disease in adulthood and help them with prevention or management. Are we improving our capacity to assess and reduce this risk? Where should we orient future research on pediatric metabolic syndrome? Host Dr. Larry Kaskel tackles these questions and more with Dr. Julia Steinberger, associate professor of pediatrics, the Dwan Endowed chair in pediatric cardiology, and director of the Pediatric Lipid Clinic at the University of Minnesota Medical School.

Brought to you by:

Guest: Karol Watson, MD, PhD

Host: Larry Kaskel, MD

Cardiometabolic risk simply includes a series of cardiovascular factors and a series of metabolic risk factors. Less easy to determine, is exactly what we can do that will effectively and efficiently reduce this risk. Dr. Karol Watson, associate professor of medicine at the University of California, Los Angeles (UCLA) David Geffen School of Medicine, and director of the UCLA Cholesterol and Lipid Management Center, takes a look at what is working, as well as the areas where we can make more progress toward suppressing the drivers of cardiovascular and metabolic diseases. Dr. Larry Kaskel hosts.

Brought to you by:

Guest: Paul Bradley, MD

Host: Larry Kaskel, MD

Many of us have experienced the frustration of seeing an obese patient who wants to make progress with their weight, but just can't achieve their desired result for any number of reasons. There is a great deal of evidence to suggest that diet and exercise, in the long run, will do more than any combination of medicines; the rub, of course, is how we get them on that magical ‘eat right and exercise' regimen. Dr. Paul Bradley, associate professor of medicine at Mercer University School of Medicine in Georgia, explains why some patients may find that a physician-centered team approach to weight loss could be their answer. Dr. Larry Kaskel hosts.

Brought to you by:

Guest: Frank Sacks, MD

Host: Larry Kaskel, MD

Dr. Frank Sacks, professor of medicine at Harvard Medical School and professor of cardiovascular disease prevention in the nutrition department at Harvard's School of Public Health, gives us an update on the long-standing debate about weight loss. New evidence from Dr. Sacks' research tells us that the specifics of macronutrient consumption appear to matter less than general calorie reduction. Yet many folks who did lose weight during this trial gained it back after its conclusion. So what's next? Can we find ways to tailor calorie-reducing diets to the preferences of each patient, or is large-scale gastric surgery the next best option for reversing our obesity epidemic? Dr. Larry Kaskel hosts.

Brought to you by:

Guest: Roger Blumenthal, MD

Host: Larry Kaskel, MD

The answer almost assuredly is patient-specific, but the question of lipid-lowering as the end or the means in measuring cardiovascular risk highlights the ongoing discussion in medicine about targets: whether how we get there is more important than just getting there. Dr. Roger Blumenthal, professor of medicine in the division of cardiology at Johns Hopkins University School of Medicine, goes beyond a focus on lipid numbers in this discussion with host Dr. Larry Kaskel. As Dr. Blumenthal explains, cost-effectiveness is a critical consideration when examining target points in lipid therapy.

Brought to you by:

Guest: Vijay Nambi, MD

Host: Larry Kaskel, MD

For many years, risk stratification has served as one of the most important tools in our efforts to lower the incidence of cardiovascular disease. Yet our tools are by no means perfect, and thus there is room for improvement. How do we move past the limitations of current biomarkers, imaging and genetic tests, enhancing our capacity to perform more accurate risk assessments? Dr. Vijay Nambi, assistant professor of medicine in the section of atherosclerosis and vascular medicine at Baylor College of Medicine, joins host Dr. Larry Kaskel to talk about a range of issues in risk stratification. How is risk scoring impacted by risk factors versus risk markers? When are 10-year risk measurements preferred over lifetime risk figures?

Brought to you by:

Guest: Miriam Vos, MD, MSPH

Host: Larry Kaskel, MD

Non-alcoholic fatty liver disease (NAFLD) is increasingly common among our young obese patients, a population for which cardiovascular disease and diabetes is a significant concern. Can measured levels of liver fat serve to help us gauge future risk for metabolic consequences in children? Host Dr. Larry Kaskel welcomes pediatric hepatologist, Dr. Miriam Vos, assistant professor in the division of gastroenterology at Emory University School of Medicine, to discuss the challenge of encouraging a young child and their family to develop habits that will promote the decline of the child's NAFLD. Dr. Vos also explores the possibility that body shape may be an important clue in the diagnosis of NAFLD, as well as current efforts to generate more accurate markers to quantify liver fat reduction during treatment.

Brought to you by:

Guest: Mary Felando, MS, RD

Host: Larry Kaskel, MD

Mary Felando, clinical dietician at the Preventive and Rehabilitative Cardiac Center at Cedars-Sinai Medical Center in Los Angeles, joins host Dr. Larry Kaskel to discuss a heart healthy diet. How can you help your patients to regard meals as medicine? And what is the best 'medicine' for them?

Brought to you by:

Guest: Eliot Brinton, MD, FAHA, FNLA

Host: Larry Kaskel, MD

Results from the recent JUPITER trial demonstrated that high-sensitivity C-reactive protein tests were strikingly effective at identifying patients whose risk of cardiovascular events and mortality could be significantly lowered with statin treatment. But do these results warrant broader screening for C-reactive protein, as some suggest? Join host Dr. Larry Kaskel and Dr. Eliot Brinton as they critically examine the JUPITER trial and the potential limitations of those findings for primary care physicians and the use of statins.

Brought to you by:

Guest: Eliot Brinton, MD, FAHA, FNLA

Host: Larry Kaskel, MD

The Women's Health Initiative trial reported that hormone replacement therapy increases the risks of coronary artery disease in postmenopausal women. Dr. Eliot Brinton, director of the metabolism section of the cardiovascular genetics department at the University of Utah School of Medicine in Salt Lake City, and a founding board member of the National Lipid Association and the American Board of Clinical Lipidology, discusses with host Dr. Larry Kaskel a new analysis of the Women's Health Initiative that disputes these findings. Dr. Brinton explores the various risks associated with estrogen, provides guidance on how to evaluate the use of estrogen in postmenopausal women, as well as the practice of stopping estrogen. Tune in to hear Dr. Brinton identify the evidence that supports the cardio-protective effects of estrogen as well the relationship between stroke and estrogen use.

Brought to you by:

Guest: Jerome D. Cohen, MD

Host: Larry Kaskel, MD

Dr. Jerome Cohen, emeritus professor of internal medicine at Saint Louis University School of Medicine and director of Preventive Cardiology Programs at the Saint Louis University Health Sciences Center, joins host Dr. Larry Kaskel to discuss the results of the National Health and Nutrition Examination Surveys (NHANES), which show that, while LDL cholesterol levels are falling, triglyceride levels in the United States are skyrocketing. These levels are five times higher than the NHANES data of the 1970s. How can we educate our patients about the serious risks associated with triglycerides, which are often ignored when addressing cardiovascular disease?

Brought to you by:

Guest: James Stein, MD

Host: Larry Kaskel, MD

Dr. James Stein, director of the Preventive Cardiology Program and the Vascular Health Screening Program at the University of Wisconsin Hospital and Clinics, discusses with host Dr. Larry Kaskel the usefulness of carotid ultrasound for the detection of cardiovascular disease in individuals that otherwise would be considered not at risk. Tune in to learn about the relationship between intima-media thickness (IMT) and heart disease, and how an IMT image of the carotid arteries can provide specific data on the individual that can be compared to the population to assess risk.

Brought to you by:

Guest: Cindy Conroy, RD, LD, MA

Host: Larry Kaskel, MD

Cindy Conroy, a registered dietitian at the Iowa Heart Center Lipid Clinic, discusses with host Dr. Larry Kaskel practical approaches to helping patients implement a successful lifestyle change program. Ms. Conroy emphasizes the importance of educating patients about the relationship between sugar intake and triglycerides, but also of thoroughly interviewing patients to determine feasible changes for the individual. Tune in to learn about the ideal staffing and facilities model for improving and supporting lifestyle change programs, and establishing a successful lipid clinic.

Brought to you by:

Host: Larry Kaskel, MD

Guest: Seth Baum, MD

For most Americans, the ratio of omega-6 to omega-3 fatty acids in their diet is about sixteen to one, an unhealthy ratio that promotes chronic diseases from heart disease to macular degeneration to colitis. Worse, omega-6s can counteract the beneficial effects of omega-3s. Dr. Seth Baum, medical director of the Integrative Heart Care Center in Boca Raton, Florida, details for host Dr. Larry Kaskel the chemical distinction between these two fatty acids. How much and what type of fish oil supplement should you recommend for your patients?

Brought to you by:

Guest: Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FCCP, FACC

Host: Larry Kaskel, MD

Dr. Peter Tóth, visiting clinical associate professor in the department of family and community medicine at the University of Illinois School of Medicine, discusses with host Dr. Larry Kaskell the key lipid clinical trials of 2008, beginning with the remarkable results of the JUPITER trial. Dr. Tóth examines the ENHANCE trial controversies, as well as the recent phenomena from long-term extension diabetic outcome trials.

Brought to you by:

Guest: Paul Ridker, MD

Host: Larry Kaskel, MD

According to a new study published in the New England Journal of Medicine, men and women who have normal cholesterol levels but signs of inflammation in the blood vessels (high levels of C-reactive protein) can cut the risk of heart attack or stroke in half. Dr. Paul Ridker, author of the study, discusses the scope and findings of the study with host Dr. Larry Kaskel as well as the controversial implications of the study. Dr. Ridker explains the remarkable correlations between high-sensitivity C-reactive protein and cardiovascular disease, and reviews the number needed treat as compared with the use of statins for persons with hyperlipidemia. Dr. Ridker identifies those class of persons who would not benefit from statin treatment, and the practical utilization of the CRP tests.

Brought to you by:

Guest: Carl Orringer, MD, FACC, FNLA

Host: Larry Kaskel, MD

Predicting the risk of heart attack is a tricky business. Dr. Carl Orringer, visiting associate professor of medicine at Case Western Reserve University School of Medicine and board-certified lipidologist who serves on the National Lipid Board of the National Lipid Association, talks with host Dr. Larry Kaskel about a non-invasive five-minute CT scan known as calcium scoring, an important tool for early detection. Dr. Orringer outlines how calcium scoring is a good predictor of cardiovascular disease and can identify patients at risk for heart attack — patients, such as women and diabetic individuals, who would not be considered candidates under traditional risk scoring models.

Brought to you by:

Guest: Douglas Jorenby, PhD

Host: Larry Kaskel, MD

Cigarette smoking is the leading preventable cause of illness and premature death in the United States, claiming over 400,000 lives a year because it directly increases the risk of dying from heart disease, stroke, emphysema, and a variety of cancers. Dr. Douglas Jorenby, director of clinical services at the Center for Tobacco Research and Intervention at the University of Wisconsin, discusses with host Dr. Larry Kaskel smoking cessation strategies for the 21st century. In addition to reviewing the research on the FDA-approved medications and nicotine replacement therapies, Dr. Jorenby talks about the relationship between smoking and cardiovascular disease. Dr. Jorenby also explains the importance of counseling in any form to support those therapies and addresses the limitations of therapies not approved by the FDA, such as hypnosis and laser therapies.

Brought to you by:

Guest: Eliot Brinton, MD, FAHA, FNLA

Host: Larry Kaskel, MD

The ADVANCE Study involved 11,140 high-risk patients with type 2 diabetes. Join host Dr. Larry Kaskel when guest Dr. Eliot Brinton explains the findings from the largest-ever study of treatments for diabetes, which provided no evidence of an increased risk of death among patients receiving aggressive treatment to lower blood glucose. Dr. Brinton highlights how the findings of the ADVANCE trial contrast the findings of the ACCORD trial, and the impact these findings will have on treatment protocols.

Brought to you by:

Guest: Terry Jacobson, MD

Host: Larry Kaskel, MD

Dr. Terry A. Jacobson explains to host Dr. Larry Kaskel the importance of non-HDL cholesterol reporting in lipid management. Dr. Jacobson describes additional lipid parameters that are emerging as valuable adjuncts to the standard panel, including measurements of apolipopprtoeins and LDL particle size and concentration. Specifically, Dr. Jacobson outlines the importance of non-HDL-C as a secondary goal of therapy, and the advantages of non-HDL measurements over traditional lipid parameter for the prediction of cardiovascular events. Most importantly, Dr. Jacobson provides the simple calculation for this measurement which is not yet reported on standard lipid panels, but is easily accessible from the information on these routine panels.

Brought to you by:

Guest: Don Wilson, MD

Host: Larry Kaskel, MD

Host Dr. Larry Kaskel welcomes Dr. Don Wilson, professor and chair of pediatrics at the Texas A&M Health Sciences Center College of Medicine, to offer his counsel on the latest guidelines for pediatric cholesterol management. Why was this the time to revise previous recommendations? How do risk factors specific to the pediatric population interface with decisions on lifestyle adjustments, diet restrictions and medication advice for your young patients?

Brought to you by:

Guest: Thomas Dayspring, MD

Host: Larry Kaskel, MD

The Interheart study identified nine easily measured factors that account for more than 90 percent of the risk of acute myocardial infarction, regardless of a patient's location, race or national origin. What are these factors, and how might they impact your practice? Host Dr. Larry Kaskel explores the implications of this study, and the potential development of uniform practice guidelines with Dr. Thomas Dayspring, clinical assistant professor of medicine at the University of Medicine and Dentistry of New Jersey.

Brought to you by:

Guest: James Ehrlich, MD

Host: Larry Kaskel, MD

The means for assessing cardiovascular risk include several new high technology developments. Dr. James Ehrlich, MD, a veteran in the development of advanced coronary risk assessment centers, educates us on the role of electron beam computed tomography (EBCT), endothelial function testing, and aspirin resistance testing in preventative cardiology. Dr. Ehrlich also examines the research concerning new biomarkers of vascular disease, such C-reactive protein and urine thrombaxane B2. Host Dr. Kaskel reviews with Dr Ehrlich the protocols for using these high tech devices prior to or in conjunction with ordering advanced imaging tests.

Brought to you by:

Guest: James Ehrlich, MD

Host: Larry Kaskel, MD

Celebrities, often criticized for their dubious influence on the public, may inadvertently promote good health when a famous celebrity dies from a heart attack. Dr. James Erhlich discusses how the sudden death of a famous person heightens the general population’s interest in cardiovascular disease risk factors. Host Dr. Larry Kaskel explores with Dr. Erlich what these public deaths reveal about risk factors that can be overlooked by treating physicians.

Brought to you by:

Guest: James Ehrlich, MD

Host: Larry Kaskel, MD

Often described as the phantom cause of heart disease, sleep apnea appears to be gaining recognition as more than just a nuisance. Host Dr. Larry Kaskel examines the connection between sleep apnea and intensified cardiac risk with Dr. James Ehrlich, chief medical officer of the cardiodiagnostic technology company Atherotech. Dr. Ehrlich details the diagnostic implications of this correlation, the importance of earlier detection, and at-home devices that can help us keep a closer eye on sleep apnea.

Brought to you by:

Guest: Penny Kris-Etherton, PhD, RD

Host Dr. Larry Kaskel welcomes Dr. Penny Kris-Etherton, PhD, RD to Lipid Luminations. Dr. Kris-Etherton is a distinguished professor of nutrition at Penn State University. The discussion will cover what health care professionals can do to increase cholestrol awareness in the general population as well as changes in guidelines and key resources that physicians can use to help with cholesterol lowering.

Brought to you by:

Guest: William S. Harris, PhD

Host: Larry Kaskel, MD

Host Dr. Larry Kaskel welcomes Dr. William Harris, professor of basic biomedical sciences, and director of the Nutrition and Metabolic Disease Research Institute at the University of South Dakota Sanford School of Medicine, who highlights key issues from the ERA JUMP study, including available testing to measure omega-3 levels in the blood, and target values for the Omega-3 Index which he pioneered.

Brought to you by:

Guest: Melvyn Rubenfire, MD

Host: Larry Kaskel, MD

Dr. Melvyn Rubenfire, professor of internal medicine and director of preventive cardiology at the University of Michigan Medical School, discusses recent findings that indicate statins may protect against cognitive deterioration among patients at high risk of dementia. How big an impact could be made by cholesterol-lowering drugs? Could we eventually incorporate statins into treatment patterns for dementia, and if so, what will it take to get us to this point? Dr. Larry Kaskel hosts.

Brought to you by:

Guest: John Baxter, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. John Baxter to Lipid Luminations. Dr. Baxter is Senior Member at The Methodist Hospital in Houston, Texas as well at the Methodist Hospital Reasearch Institute. He will be discussing Thyroid Hormone Receptor Beta and Tissue Selective Uptake Antagonists. In particular, how they relate to the treatment of Atherosclerosis, Obesity and Diabetes. Selective thyroid hormone receptor subtype-beta (TRbeta) agonists have received attention as potential treatments for hypercholesterolemia and obesity, but have received less attention as treatments for diabetes.

Brought to you by:

Guest: Alan S. Brown, MD, FACC, FAHA, FNLA

Host: Larry Kaskel, MD

To effectively reduce one's cardiovascular risk, recent studies suggest it is necessary to treat multiple factors and not just the patient's LDL number. Dr. Brown discusses with host Dr. Larry Kaskel how studies that used a multi-factor approach, such as the Steno studies and the Champ study, dramatically reduced the incidents of cardiovascular events. Advance lipid testing according to Dr. Brown should only be used for borderline patients, and is not necessary for patients where the risk is apparent from the general blood/lipid panel numbers. Dr. Brown also highlights the need for a prospective clinical trial, which focuses on non-HDL numbers and particles.

Brought to you by:

Guest: Catherine McNeal, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Catherine McNeal to Lipid Luminations. Dr. McNeal is an Associate Professor of Pediatrics and Associate Professor of Internal Medicine at The Texas A&M Health Science Center, College Station, Texas. Dr. McNeal will discuss the features of metabolic syndrome in children and adolescents and why early intervention is so important. She will also talk about the problem in diagnosing the metabolic syndrome in youth based on the dynamic changes in the parameters associated with growth and maturation.

Brought to you by:

Guest: Yehuda Handelsman, MD

Host: Larry Kaskel, MD

Host Dr. Larry Kaskel welcomes Dr. Yehuda Handelsman, medical director of the Metabolic Institute of America and chair of the International Committee for Insulin Resistance. Dr. Handelsman examines the relationship of insulin resistance to metabolic syndrome, as well as a series of clinical conditions associated with insulin resistance. He also highlights lifestyle modifications and other treatment measures for patients with multiple risk factors.

Brought to you by:

Guest: Alan S. Brown, MD, FACC, FAHA, FNLA

Host: Larry Kaskel, MD

Host Dr. Larry Kaskel welcomes Dr. Alan Brown, medical director of the Midwest Heart Disease Prevention Center in Naperville, Illinois, to discuss targets of lipid therapy. What are the calculated risk assessments for major cardiovascular events among patients with coronary disease, diabetes and other common risk factors? In these cases, when are statin therapies not enough to provide optimal care? Dr. Brown also opines on the value of residual risk measurements.

Brought to you by:

Guest: Allan Sniderman, MD

Host: Larry Kaskel, MD

Consensus is building around apolipoprotein B (apoB) as the preferred tool for gauging the effectiveness of LDL-lowering therapies. Is it accurate, reproducible and cost-effective? Host Dr. Larry Kaskel welcomes Dr. Allan Sniderman, professor of cardiology at the McGill University Health Centre in Montreal, for a noteworthy discussion about apoB and its impact on our approach to atherogenic risk management. Will this test soon become standard in a lipid panel?

Brought to you by:

Guest: Tara Dall, MD

Host: Larry Kaskel, MD

Host Dr. Larry Kaskel welcomes Dr. Tara Dall, board-certified lipidologist at Advanced Lipidology in Wisconsin, to discuss chronic anovulation and hyperandrogenism, and its association with an increased risk of diabetes, metabolic syndrome and cardiac problems. She will also highight treatment options.

Brought to you by:

Guest: Donna Polk, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Donna Polk to Lipid Luminations. Dr. Polk is Director of Preventive Cardiology at Hartford Hospital in Hartford, Conneticut. Dr. Polk will discuss LDL Apheresis and the evidence supporting its use, what the procedure entails as well as who is eligible and where it is performed.

Brought to you by:

Guest: Michael Richman, MD

Host: Larry Kaskel, MD

Heart disease is the number one killer of both men and women in the United States notwithstanding the performance of over 125 million lipid panel. Guest Dr. Michael Richman discusses with host Dr. Larry Kaskel various advance cholesterol testing mechanism that could provide the necessary information to reduce the risk of a cardiovascular event. Dr. Richman also explains why advanced cholesterol testing is not performed more routinely and often omitted for even those patients presenting the greatest risk factors.

Brought to you by:

Guest: Robert Wild, MD, MPH, D.Phil.

Host: Larry Kaskel, MD

Many studies suggest that metabolic syndrome is a more accurate predictor of cardiovascular disease in women, many of whom are vulnerable to the disease process starting in their late teenage years and extending post-menopause. Is there an ideal age at which to begin focusing our attention here? Host Dr. Larry Kaskel welcomes Robert Wild, MD, PhD, MPH, professor of reproductive endocrinology at the University of Oklahoma College of Medicine, to tackle questions on atherosclerotic cardiovascular disease and its link to metabolic syndrome.

Brought to you by:

Guest: William Boden, MD, FACC, FAHA

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. William Boden to Lipid Luminations. Dr. Boden is the medical director of cardiovascular services at Kaleida Health and chief of cardiology at Buffalo General and Millard Fillmore Hospitals. Dr. Boden is extremely well-versed on the COURAGE Trial and will explore where COURAGE provides clarity of management and where its results leave us with uncertainty.

Brought to you by:

Guest: Kevin Williams, MD

Host: Larry Kaskel, MD

Host Dr. Larry Kaskel welcomes Dr. Kevin J. Williams, professor of medicine and professor of biochemistry and molecular biology in the division of endocrinology at Thomas Jefferson University , to discuss rapid regression and stabilization of athlerosclerosis. How can this be achieved pharmacologically, even in patients with advanced plaques? Dr. Williams also highlights effective measures to improve plasma lipoprotein profiles.

Brought to you by:

Guest: Perry Weinstock, MD

Host: Larry Kaskel, MD

Host Dr. Larry Kaskel welcomes Dr. Perry Weinstock, director of clinical cardiology at Cooper University Hospital and associate professor of medicine at the UMDNJ-Robert Wood Johnson Medical School, to evaluate the clinical implications of the COURAGE Trial, in part, through a review of its optimal medical therapies. In the context of this trial, how can we work with our patients to truly optimize medical therapy?

Brought to you by:

Guest: David T. Nash, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. David T. Nash to Lipid Luminations. Dr. Nash is with Syracuse Preventive Cardiology and will discuss how lipid abnormalities and genetic markers are associated with an increased risk for cardiovascular disease and cognitive impairment. He will also speak about how patients with hypertension who are treated experience fewer cardiovascular disease events as well as less cognitive impairment than similar untreated patients.

Brought to you by:

Guest: Michael H. Davidson, MD

Host: Larry Kaskel, MD

Host Dr. Larry Kaskel welcomes Dr. Michael Davidson, Director of Preventive Cardiology at the University of Chicago School of Medicine and Executive Medical Director of Radiant Research in Chicago. Dr. Davidson will discuss C-reactive protein (CRP) levels and other emerging biomarkers as well as new drugs on the horizon.

Brought to you by:

Guest: James Ehrlich, MD

Host: Larry Kaskel, MD

Host Dr. Larry Kaskel is joined by Dr. James Ehrlich, chief medical officer of Atherotech, the Birmingham-based company that has developed the VAP lipid test, and clinical associate professor of endocrinology at University of Colorado School of Medicine. They will discuss common misconceptions in such areas as: the value of standard cholesterol tests, HDL and LDL numbers, particle numbers as a good predictor of risk, and coronary calcium.

Brought to you by:

Guest: James Ehrlich, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. James Ehrlich, chief medical officer of Atherotech and clinical associate professor in the endocrinology division of the University of Colorado School of Medicine, who has developed advanced coronary risk assessment programs in four U.S. cities. Dr. Ehrlich will describe evidence suggesting that office-based risk assessment (Framingham) fails to identify high risk individuals. He will detail which patients need advanced lipid testing as well as discuss tools and emerging biomarkers that are of highest value.

Brought to you by:

Guest: Donald Lloyd-Jones, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel is joined by Dr. Donald Lloyd-Jones, Associate Professor of Preventive Medicine at Northwestern University and a practicing preventive cardiologist at Northwestern Memorial Hospital. They will discuss the current state of the art as well as improvements on CVD risk prediction. They will also discuss what lifetime risk estimates tell us and how to achieve low lifetime risk.

Brought to you by:

Guest: Paolo Raggi, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Paolo Raggi to Lipid Luminations. Dr. Raggi is Professor of Medicine-Cardiology and Professor of Radiology at Emory Universtiy. The discussion will focus on whether risk assessment may be improved by additional tests such as coronary artery calcium scoring (CACS). Can a change in calcium score be used to assess the efficacy of lipid therapy?

Brought to you by:

Guest: Peter Jones, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Peter Jones to Lipid Luminations. Dr. Jones is Associate Professor in the Center for Cardiovascular Disease Prevention of the Methodist DeBakey Heart Center and Baylor College of Medicine in Houston. They will discuss how common statin intolerance is and what other drug options exist to lower LDL-C. They will further explore the side effects of these other options and whether or not they reduce CHD risk.

Brought to you by:

Guest: Jerome D. Cohen, MD

Host: Larry Kaskel, MD

Dr. Kaskel welcomes Dr. Jerome Cohen to Lipid Luminations. Dr. Cohen is a cardiologist and professor of medicine and cardiology at St. Louis University where he also serves as the director of preventive cardiology. They will be delving into the controversial issues of The Enhance Study plus discussing what doctors should be recommending in the wake of the results.

Brought to you by:

Guest: Carol Mason, ARNP

Host: Larry Kaskel, MD

Dr. Larry Kaskel is joined by Carol Mason, Clinical Director, Division of Preventive Cardiology University of Southern Florida. Ms. Mason will answer, "Why should any professional become a Clinical Lipid Specialist?". She will also discuss who is eligible, what are the requirements and how the ACCL differs from the American Board of Clinical Lipidology.

Brought to you by:

Guest: Neil Stone, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel is joined by Dr. Neil Stone, Professor of Clinical Medicine in the Department of Cardiology and a Preventive Cardiologist at Northwestern University in Chicago. He is an expert on nutrition and heart disease and has been a member of the AHA nutrition committee, as well as the National Cholesterol Education Program Adult Treatment Panel. Tune in to hear about the pros and cons found in each of low, moderate and high fat diets. Dr. Stone will highlight recommended diets by the AHA and the National Cholesterol Education Program as well as delve into the benefits of the Mediterranean style diet. He will also discuss the habits and traits of people who are able to keep weight off successfully.

Brought to you by:

Guest: William Howard, MD

Host: Larry Kaskel, MD

Host Dr. Larry Kaskel welcomes Dr. William James Howard, professor of medicine at George Washington University School of Medicine and Health Sciences. Dr. Howard has studied metabolic syndrome (MS) for over 25 years and will be discussing differences among ethnic groups in the prevalence of MS as well as lifestyle and pharmacologic therapies for MS.

Brought to you by:

Guest: Daniel Rader, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Daniel Rader to Lipid Luminations. Dr. Rader is Professor of Medicine, Pharmacology, and Pathology and Laboratory Medicine at University of Pennsylvania. He is the Director of Preventive Cardiovascular Medicine and Lipid Clinic Director at General Clinical Research Center. The discussion will center around HDL and how important it is as a risk factor, what levels are considered low, and current targeted therapies as well as those in development.

Brought to you by:

Guest: David Maron, MD

Host: Larry Kaskel, MD

Dr Larry Kaskel is joined by Dr. David Maron, Associate Professor of Medicine and Emergency Medicine, Vanderbilt University and Chairman, Optimal Medical Therapy Committee, COURAGE Trial. Tune in to hear about the clinical characteristics of the patient participants as well as risk factor changes, patient adherence and clinical implications of the trial.

Brought to you by:

Guest: David Maron, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel is joined by Dr. David Maron, Associate Professor of Medicine and Emergency Medicine, Vanderbilt University School of Medicine and Chairman, Optimal Medical Therapy Committee, COURAGE Trial. They will discuss the COURAGE trial, analyze the criticisms of the trial, and further discuss the results and findings.

Brought to you by:

Guest: W. Virgil Brown, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Virgil Brown to Lipid Luminations. Dr. William Virgil Brown, Editor-in Chief of the Journal of Clinical Lipidology and Charles Howard Candler Professor of Medicine at Emory University School of Medicine. Tune in to hear about neclear physicist, John Gofman and the major contributions he made to science and how it affects cholesterol work today.

Brought to you by:

Host: Larry Kaskel, MD

Guest: William S. Harris, PhD

Dr. Larry Kaskel welcomes Dr. William Harris to Lipid Luminations. Dr. Harris is Research Professor in the Department of Medicine at Sanford School of Medicine, University of South Dakota. They will discuss sources, alternatives and impacts of Omega 3 fatty acids.

Brought to you by:

Guest: Paulo Raggi, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel of Lipid Luminations takes microphone in hand on the floor of the Midwest Lipid Association Conference to ask thought leaders in the field what's on their minds with regards to lipids.

Brought to you by:

Tune in to hear Dr. Larry Kaskel on site at the Lipid Conference. In this first of a two part series, Dr. Kaskel catches top thought leaders at the conference to get their candid remarks on important lipid topics.

Brought to you by:

Guest: Michael H. Davidson, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel is joined by Dr. Michael Davidson, Director of Preventive Cardiology at The University of Chicago. Tune in as they discuss new investigational compounds and statin safety.

Brought to you by:

Guest: John Foreyt, MD

Host: Larry Kaskel, MD

Host Dr. Larry Kaskel welcomes John Foreyt, PhD, professor in the departments of medicine, pediatrics and psychiatry, and director of the DeBakey Heart Center’s Behavioral Medicine Research Center at Baylor College of Medicine. What are today’s trends in diet counseling? Are we finding that certain behavior modification steps are more successful than others? The answer always comes back to one word: calories.

Brought to you by:

Guest: Susan Lynch, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel is joined by Dr. Susan Lynch, a pediatric lipid specialist at the Cholesterol Treatment Center at Concord Hospital. Dr. Lynch is also the First Lady of New Hampshire and will discuss, among other things, the defintion of overweight and obesity in pediatrics, the inherent complications, and how we can advocate for healthier eating in our communities.

Brought to you by:

Guest: Anthony Busti, PharmD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Anthony Busti, clinical lipid specialist, to Lipid Luminations. They will discuss HIV patients with regards to antiretrovirals and dyslipidemia and other special issues in this patient population.

Brought to you by:

Host: Larry Kaskel, MD

Guest: Ralph LaForge

This week on Lipid Luminations, Dr. Larry Kaskel welcomes Ralph LaForge, Mangaging Director of the Duke Lipid Disorder Physician Education Program at Duke University. They will discuss scientifically proven dietary regimens and supplements, plus metabolic syndrome, resistance training, and more.

Brought to you by:

Guest: Christie Ballantyne, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Christie Ballantyne to Lipid Luminations. Dr. Ballantyne is Director of the Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, and chief of the section of Atherosclerosis and Vascular Medicine at the Baylor College of Medicine. Find out the real deal on particle size versus number, as well as when to measure other new markers and what to do with abnormal results.

Brought to you by:

Guest: Louis Aronne, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Louis Aronne to Lipid Luminations. Dr. Aronne is a leading authority on obesity and its treatment. He is Clinical Professor of Medicine at Weill-Cornell Medical College and has an adjunct appointment at Columbia University College of Physicians and Surgeons. He is Director of the Comprehensive Weight Control Program, a state-of-the-art, multidisciplinary obesity research and treatment program. He will discuss the differences between cardiometabolic risk and cardiovascular risk and their implications, treatments, etc.

Brought to you by:

Dr. Larry Kaskel welcomes Dr. Evan Stein to Lipid Luminations. Dr. Stein is Professor of Pathology/Laboratory Medicine and Associate Professor of Internal Medicine at the University of Cincinnati. In 1972 Dr. Stein formed the first Lipid Clinic in South Africa. He will be enlightening us about subfractions and how, why and if we should be paying attention to the.

Guest: James Mckenney, PharmD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. James Mckenney to Lipid Luminations. Dr. Mckenney is Professor emeritus with Virginia Commonwealth University and founding member of the National Cholesterol Education Program. They will discuss Niacin, Fibrates and Omega 3 Fatty Acids.

Brought to you by:

Guest: James Mckenney, PharmD

Host: Larry Kaskel, MD

Dr. Larry Kaskel is joined by Dr. James McKenney, Professor emeritus with Virginia Commonwealth University and founding member of the National Cholesterol Education Program. Dr. Mckenney will discuss liver, muscle and renal safety with regard to statins.

Brought to you by:

Guest: Ronald Goldberg, MD

Host: Larry Kaskel, MD

This week joining Dr. Kaskel on Lipid Luminations is Dr. Ronald Goldberg who serves as Associate Director of Medical Affairs of the Diabetes Research Institute, and Director of the Lipid Disorders Unit. Dr. Goldberg will discuss features, causes, identification and management of diabetic dyslipidemia.

Brought to you by:

Guest: Greg Brown, MD, PhD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Greg Brown to Lipid Luminations. Dr. Brown is a Professor of Medicine, Cardiology Division at University of Washington School of Medicine. Tune in to learn what affects traditional lipid risk variables and what combinations are most favorable.

Brought to you by:

Guest: Peter Toth, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Peter Toth to Lipid Luminations. Dr. Toth is the Director of Preventive Cardiology at Sterling Rock Falls Clinic and he will talk about why it is important to treat beyond LDL-C and the role of combination therapy, recent clinical trials and performing risk estimation.

Brought to you by:

Guest: Mary McGowan, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Mary McGowan to Lipid Luminations. Dr. McGowan is Director of the Cholesterol Treatment Center at Concord Hospital and Member of the New Hampshire Childhood Obesity Expert Panel. They will be discussing Pediatric Dyslipidemia as secondary to genetics and obesity.

Guest: Mary McGowan, MD

Host: Larry Kaskel, MD

Dr. Larry Kaskel welcomes Dr. Mary McGowan to Lipid Luminations. Dr. McGowan is Director of the Cholesterol Treatment Center and Author of: Heart Fitness for Life. They will discuss the different trends is cholesterol lowering over the years.

Brought to you by:

Host: Larry Kaskel, MD

Guest: Thomas Dayspring, MD

Dr. Larry Kaskel is joined by Dr. Thomas Dayspring for Lipid Luminations. Dr. Dayspring, a certified menopause practitioner will discuss menopause and its effect on lipids.

Guest: Thomas Dayspring, MD

Host: Larry Kaskel, MD

Dr. Thomas Dayspring, a specialist in postmenopausal lipidology, joins Dr. Larry Kaskel for Lipid Luminations. They will be discussing all things current with regard to women and cardiovascular disease.

Brought to you by:

Guest: Jerome D. Cohen, MD

Host: Larry Kaskel, MD

Join Dr. Larry Kaskel as he welcomes Dr. Jerome Cohen, cardiologist and professor of medicine and cardiology at St. Louis University to speak about his published algorithm addressing preventive cardiology. The interview marks the first in a series entitled, "Lipid Luminations".

Brought to you by:

Guest: Tara Dall, MD

Host: Larry Kaskel, MD

Dr. Kaskel speaks with guest Dr. Tara Dall about making the move to full time lipidologist. She discusses the community she serves and the clinic set up.. involvement of NPs and dietitians, etc. She also discusses the benefits of advanced lipid testing.

Brought to you by: